SCHEMBL24596343

SCHEMBL24596343

FC(F)(F)c1ccc(Br)c(Nc2cccnc2C(F)(F)F)n1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SYK P43405 5/20 0.37
SLC40A1 Q9NP59 2/20 0.37
GRM5 P41594 1/20 0.37
TAS2R14 Q9NYV8 2/20 0.36
MAT2A P31153 1/20 0.35
IGF1R P08069 1/20 0.34
DHODH Q02127 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
GRM4 Q14833 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
TGFBR1 P36897 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24596302 0.86 MAT2A (0.39) SYKSLC40A1GRM5TAS2R14MAT2A
SCHEMBL26631683 0.83 GRM5 (0.41) SYKSLC40A1GRM5TAS2R14DHODH
SCHEMBL24596212 0.83 ULK1 (0.44) SYKSLC40A1GRM5MAT2AMEN1
SCHEMBL24596205 0.82 MAT2A (0.40) SYKSLC40A1GRM5TAS2R14MAT2A
SCHEMBL24122973 0.80 TGFBR1 (0.40) SYKSLC40A1GRM5TAS2R14MAT2A
SCHEMBL24596297 0.79 EPHX2 (0.47) TAS2R14KDM4EMEN1ALDH1A1MAPT
SCHEMBL24596390 0.79 LMNA (0.45) TAS2R14IGF1RHDAC6KDM4EMEN1
SCHEMBL24596277 0.79 GRM5 (0.41) SYKGRM5KDM4EMEN1MAPT
SCHEMBL24596363 0.79 TAS2R14 (0.52) SYKTAS2R14DHODHHDAC6MEN1
SCHEMBL24596182 0.78 CCR4 (0.40) HDAC6MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A SYK 4805/4885SLC40A1 3158/4885GRM5 2254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.